FDA moves to remove GLP-1 medications from 503B Bulks List

• On April 30, 2026, the U.S. FDA introduced it’s contemplating eradicating GLP-1 drugs from the 503B bulks listing.
• FDA’s 503B bulks listing identifies drug substances that outsourcing amenities can use to compound drugs.
• Consultants agree eradicating GLP-1s from the 503B bulks listing will considerably decrease the provision of compounded GLP-1s medicine.
• Sufferers should still have the ability to obtain compounded GLP-1s via 503A compounding pharmacies, and take into account reliable options for weight reduction.

In accordance with the FDA’s announcement, the group is asking for submitted feedback for or towards this resolution by the tip of June 2026 earlier than making their ultimate willpower.

Medical Information Right this moment spoke with 4 weight problems specialists to seek out out extra about what the FDA’s 503B bulks listing is, the potential future availability of compounded GLP-1 drugs, and what options could also be accessible for customers who might not have the ability to afford the model title medicine.

In accordance with Douglas Ewing, MD, FACS, DABOM, a board-certified bariatric surgeon and medical director of the Middle for Weight Loss and Metabolic Well being at Hackensack College Medical Middle, and affiliate professor of surgical procedure at Hackensack Meridian Faculty of Drugs in New Jersey, the FDA’s 503B bulks listing identifies bulk drug substances that outsourcing amenities can use to compound drugs.

“These outsourcing amenities, regulated underneath part 503B of the Federal Meals, Drug, and Beauty Act, can produce bigger batches of compounded medicine than conventional 503A compounding pharmacies, which compound for particular person sufferers with particular prescriptions,” Ewing defined to MNT.

“The essential distinction between a drug on the 503B listing and an FDA-approved treatment is the extent of scrutiny,” he continued.

“FDA-approved medicine endure an extended and rigorous strategy of medical trials to show their security, effectiveness, and high quality earlier than they are often marketed to the general public.”

“Compounded medicine, even from 503B amenities, don’t undergo this identical pre-market approval course of. Whereas 503B amenities are required to observe present Good Manufacturing Practices (cGMP), the compounded medicine themselves usually are not FDA-approved.”

If semaglutide and tirzepatide are faraway from the 503B bulks listing, the provision of compounded GLP-1s would drop considerably, Michael Snyder, MD, FACS, FASMBS, DABOM, medical director of the Bariatric Surgical procedure Middle at Rose Medical Middle, founder and director of the Denver Middle for Bariatric Surgical procedure Basis, and in-house weight problems specialist at FuturHealth, informed MNT.

“Most present compounded provide is produced via 503B outsourcing amenities, which might not have the ability to compound them in bulk,” Snyder mentioned.

“There should still be restricted use underneath 503A compounding guidelines, the place a drugs is ready for a person affected person based mostly on a particular medical indication, however that pathway is far more restricted and never designed for widespread use.”

Jen Manne-Goehler, MD, ScD,assistant professor of drugs at Harvard Medical Faculty, agreed.

“There could also be some types of compounded GLP-1 medicine nonetheless accessible regardless of this resolution,” Manne-Goehler informed MNT.

”Particularly, the FDA’s resolution to not embrace these GLP-1s on the majority compounding listing wouldn’t be anticipated to have an effect on their use by 503A pharmacies. 503A compounding pharmacies compound in accordance with particular affected person prescriptions and are required by state boards of pharmacy to adjust to requirements.”

Due to the recognition and excessive demand of GLP-1 drugs, Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Middle at Orange Coast Medical Middle in Fountain Valley, CA, fearful this may increasingly drive some folks to buy their treatment via a probably unsafe choice.

“What I believe will occur is folks will attempt to get the drugs from different sources exterior the U.S., and that may be a little riskier,” Ali informed MNT.

“You can not be getting the treatment you’re shopping for, you might be getting one thing totally different or one thing possibly even unsafe. So it could improve some threat if persons are going to go to sources exterior of the U.S. to attempt to get these drugs.”

When requested concerning the security of compounded GLP-1 medicine, Ewing mentioned that may be a complicated query with out a easy “sure” or “no” reply. “The security of compounded GLP-1s can fluctuate considerably relying on the supply,” he defined.

“There are reliable compounding pharmacies that adhere to high-quality requirements. Nevertheless, the shortage of FDA approval and oversight for the ultimate compounded merchandise introduces inherent dangers.”

– Douglas Ewing, MD, FACS, DABOM

“Issues have been raised concerning the potential for contamination, impurities, and incorrect dosages in some compounded merchandise,” Ewing continued.

“There have additionally been cases of pharmacies utilizing totally different salt types of semaglutide, which haven’t been permitted by the FDA and whose security and efficacy are unknown.”

Manne-Goehler mentioned that many stories have steered that the present compounded GLP-1s have the next variety of extreme unwanted side effects.

“As an example, one study confirmed that compounded GLP-1 RAs are related to a better threat of adversarial occasions, security issues, and product high quality points in comparison with non-compounded merchandise,” she detailed.

“This can be as a result of decrease high quality compounding practices may end up in points with drug high quality, contamination or variations within the quantity of lively ingredient. A number of medical societies have really helpful towards the usage of compounded GLP-1 therapies.”

If compounded GLP-1s develop into much less accessible, Snyder mentioned there are nonetheless reliable, evidence-based choices for weight reduction.

“That features different FDA-approved drugs for weight administration, in addition to structured medical weight loss programs that mix vitamin, behavioral help, and ongoing medical monitoring,” he continued.

“We additionally anticipate that over time these drugs will develop into extra inexpensive and protection ought to develop over time. However, clearly, not quickly.”

Ali mentioned there are different drugs accessible which might be possibly accessible in generic kind as a result of they’ve been round longer, however they don’t work fairly the identical, or possibly not even fairly in addition to the GLP-1 drugs.

“So there are different choices accessible, however they might be much less efficient,” he added.

For many who could also be fearful about affording the name-brand GLP-1 drugs, Ewing mentioned it’s all the time worthwhile to examine together with your insurance coverage supplier about their protection for weight-loss drugs, as formularies can change, and what was not lined earlier than is likely to be now.

“Many pharmaceutical firms provide copay playing cards and affected person help applications that may considerably cut back the out-of-pocket value of brand-name GLP-1s for eligible people,” he detailed. “Companies like GoodRx can provide important financial savings on brand-name GLP-1 drugs for these paying out-of-pocket.”

“It’s important for sufferers presently utilizing compounded GLP-1s to have an open dialog with their healthcare supplier to discover these options and develop a protected and efficient remedy plan transferring ahead,” Ewing added.